An Open-label, Phase II Study of the Safety and Tolerability of Pirfenidone in Patients with Scleroderma-associated Interstitial Lung Disease: the LOTUSS Trial

2016262 citationsJournal Articlebronze Open Access

Authors

ClinicalTrials.gov; www.clinicaltrials.gov NCT01933334.

Good health and well-being

Published in: The Journal of Rheumatology

Volume 43, Issue 9, pp. 1672-1679

Field-Weighted Citation Impact: 21.02